EU HTA – Achieving Broad Access Fast! What Will It Take For Innovative Medicines To Succeed?

The EU Health Technology Assessment Regulation (EU HTAR) is revolutionizing the pharmaceutical sector. Starting January 12, 2025, oncology drugs and advanced therapy medicinal product (ATMP) producers will be required to undergo the Joint Clinical Assessment (JCA) procedure. It is a historic step that will revolutionize the evaluation and introduction of innovative medicines to market in Europe.

Cencora's subject matter experts will take you through the complexities of the EU HTAR and what it implies. In this webinar, Herbert Altmann, Vice President of Europe's Market Access and Healthcare Consulting at Cencora, moderates a panel discussion with leading industry experts. Hear Iga Lipska, François Meyer, and Oriol Solà-Morales speak on navigating regulatory challenges and achieving timely patient access to innovative medicines.

Stay current and empowered with proven strategies to succeed under the new regulations. Don’t let this opportunity slip you up to learn directly from top industry professionals.

Click below to access the full webinar.